e sabong jay costura
2025-01-12

Indiana offering small businesses grants of up to $15,000 for professional servicesBETHLEHEM, Pa., Dec. 19, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. ("OTI") OSUR , a leader in point-of-need and home diagnostic tests and sample management solutions, today announced the acquisition of Sherlock Biosciences, Inc., a global health company bringing next-generation diagnostics to consumers and healthcare providers. This acquisition expands OraSure's innovation pipeline with the addition of Sherlock's molecular diagnostics platform, which is able to provide rapid results with strong sensitivity and specificity in a disposable format that is well-suited for over-the-counter usage. Sherlock's first molecular self-test is for Chlamydia Trachomatis (CT) and Neisseria Gonorrhoeae (NG) which will expand OraSure's portfolio of rapid diagnostics for sexually transmitted infections (STIs), subject to regulatory approvals. Test results are expected to be provided in under 30 minutes by analyzing DNA and RNA from self-collected swabs using isothermal amplification. In addition, Sherlock has been developing a pipeline of other molecular tests, along with several next-generation technology platforms, including Ambient Temperature Amplification and CRISPR-based technologies that have the potential to further reduce costs and improve performance of its platforms. Sherlock's CT/NG self-test is in clinical studies and is expected to be submitted to the FDA by the end of 2025 for review. Subject to regulatory approvals, revenue from Sherlock's CT/NG test is expected to contribute to OTI's growth beginning in 2026, benefitting from OraSure's existing infrastructure, commercial capabilities, and strong customer relationships. OTI estimates that testing for CT/NG represents a total addressable market of more than $1.5 billion. The vast majority of CT/NG tests in the U.S. are processed in a centralized lab, and the introduction of an affordable, rapid self-test has the potential to drive significant incremental market expansion. Additionally, public health channels play a key role in STI screening, which is an area where OraSure has a strong presence. "The acquisition of Sherlock represents the next step in OTI's innovation strategy," said Carrie Eglinton Manner, President and CEO of OraSure. "Sherlock brings valuable capabilities with an advanced molecular platform that aims to deliver lab-like accuracy in a format that expands access to diagnostic insights through convenient, effortless tests. We are excited to welcome Sherlock's talented team to OTI and believe that Sherlock's unique capabilities will contribute significantly to the expansion of our pipeline of diagnostic tests in infectious disease, sexual health, and beyond." Conference Call Information OraSure will host a conference call to discuss the acquisition of Sherlock Biosciences at 5:00 p.m. ET on Thursday, Dec. 19, 2024. A webcast of the conference call will be available on the investor relations page of OraSure's website at https://orasure.gcs-web.com/events-and-presentations . Please click on the webcast link and follow the prompts for registration and access at least 10 minutes prior to the call. The webcast will be archived on OraSure's website shortly after the call has ended and will be available for approximately 90 days. To participate in the live conference call, please follow the link below to pre-register. After registering, you will be provided with access details via email. https://register.vevent.com/register/BIb938f5bae2a442d9acdb83f4bdd9286d About OraSure Technologies, Inc. OraSure Technologies, Inc. ("OraSure") transforms health through actionable insight and powers the shift that connects people to healthcare wherever they are. OraSure improves access, quality, and value of healthcare with innovation in effortless tests and sample management solutions. OraSure, together with its wholly-owned subsidiary, DNA Genotek Inc., is a leader in the development, manufacture, and distribution of rapid diagnostic tests and sample collection and stabilization devices designed to discover and detect critical medical conditions. OraSure's portfolio of products is sold globally to clinical laboratories, hospitals, physician's offices, clinics, public health and community-based organizations, research institutions, government agencies, pharmaceutical companies, and direct to consumers. For more information on OraSure Technologies, please visit www.orasure.com Forward Looking Statements This press release contains certain "forward-looking statements" within the meaning of the Federal securities laws, including with respect to products, product development and manufacturing activities, the Company's acquisition of Sherlock, revenue growth, cash flow, increasing margins and other matters. Words such as "expects," "estimates," "forecasts," "intends," "plans," "projects," "could," "may," "should," "will" or other similar words and expressions are intended to identify these forward-looking statements. Forward-looking statements are not guarantees of future performance or results. Known and unknown factors that could cause actual performance or results to be materially different from those expressed or implied in these statements include, but are not limited to: the Company's ability to integrate Sherlock's business and achieve the intended benefits of the acquisition on the timeline expected or at all; Sherlock's ability to seek and obtain regulatory approval for products in development; the Company's ability to satisfy customer demand; ability to reduce the Company's spending rate, capitalize on manufacturing efficiencies and drive profitable growth; ability to achieve the anticipated cost savings as a result of the Company's business restructuring, including from insourcing third party manufacturing and exiting microbiome services; ability to market and sell products, whether through the Company's internal, direct sales force or third parties; impact of significant customer concentration in the genomics business; failure of distributors or other customers to meet purchase forecasts, historic purchase levels or minimum purchase requirements for the Company's products; ability to manufacture or have manufactured products in accordance with applicable specifications, performance standards and quality requirements; ability to obtain, and timing and cost of obtaining, necessary regulatory approvals for new products or new indications or applications for existing products; ability to comply with applicable regulatory requirements; ability to effectively resolve warning letters, audit observations and other findings or comments from the FDA or other regulators; the impact of the novel coronavirus ("COVID-19") pandemic on the Company's business, supply chain, labor force, ability to successfully develop new products, validate the expanded use of existing collector products, receive necessary regulatory approvals and authorizations and commercialize such products for COVID-19 testing, and demand for the Company's COVID-19 testing products; changes in relationships, including disputes or disagreements, with strategic partners or other parties and reliance on strategic partners for the performance of critical activities under collaborative arrangements; ability to meet increased demand for the Company's products; impact of replacing distributors; inventory levels at distributors and other customers; ability of the Company to achieve its financial and strategic objectives and continue to increase its revenues, including the ability to expand international sales and the ability to continue to reduce costs; impact of competitors, competing products and technology changes; reduction or deferral of public funding available to customers; competition from new or better technology or lower cost products; ability to develop, commercialize and market new products; market acceptance of oral fluid or urine testing, collection or other products; market acceptance and uptake of microbiome informatics, microbial genetics technology and related analytics services; changes in market acceptance of products based on product performance or other factors, including changes in testing guidelines, algorithms or other recommendations by the Centers for Disease Control and Prevention or other agencies; ability to fund research and development and other products and operations; ability to obtain and maintain new or existing product distribution channels; reliance on sole supply sources for critical products and components; availability of related products produced by third parties or products required for use of the Company's products; impact of contracting with the U.S. government; impact of negative economic conditions; ability to maintain sustained profitability; ability to utilize net operating loss carry forwards or other deferred tax assets; volatility of the Company's stock price; uncertainty relating to patent protection and potential patent infringement claims; uncertainty and costs of litigation relating to patents and other intellectual property; availability of licenses to patents or other technology; ability to enter into international manufacturing agreements; obstacles to international marketing and manufacturing of products; ability to sell products internationally, including the impact of changes in international funding sources and testing algorithms; adverse movements in foreign currency exchange rates; loss or impairment of sources of capital; ability to attract and retain qualified personnel; exposure to product liability and other types of litigation; changes in international, federal or state laws and regulations; customer consolidations and inventory practices; equipment failures and ability to obtain needed raw materials and components; cybersecurity breaches or other attacks involving the Company's systems or those of the Company's third-party contractors and IT service providers; the impact of terrorist attacks, civil unrest, hostilities and war; and general political, business and economic conditions, including inflationary pressures and banking stability. These and other factors that could affect the Company's results are discussed more fully in the Company's filings with the Securities and Exchange Commission (the "SEC"), including the Company's registration statements, Annual Report on Form 10-K for the year ended December 31, 2023, Quarterly Reports on Form 10-Q, and other filings with the SEC. Although forward-looking statements help to provide information about future prospects, readers should keep in mind that forward-looking statements may not be reliable. Readers are cautioned not to place undue reliance on the forward-looking statements. The forward-looking statements are made as of the date of this press release and the Company undertakes no duty to update these statements. Investor Contact: Media Contact: Jason Plagman Amy Koch VP, Investor Relations Director, Corporate Communications investorinfo@orasure.com media@orasure.com © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
The construction industry, known for its demanding work conditions and tight margins, often places workers in vulnerable positions where they may feel compelled to endure exploitative practices in order to make ends meet. The lack of effective oversight and accountability mechanisms further exacerbates the risks faced by workers, leaving them with few avenues for recourse when disputes arise.The public officials involved in the case were implicated in the illegal production and distribution of Ba Bao Dan, using their influence to circumvent regulatory procedures and promote the product through deceptive marketing tactics. Their actions not only violated industry regulations but also compromised the health and safety of consumers who trusted the product's purported benefits.
Moreover, Nvidia's track record on corporate responsibility and ethical practices has faced criticism in recent years. From allegations of labor rights violations in its supply chain to concerns over environmental impact, Nvidia has come under fire for a range of issues that have eroded public trust and investor confidence.In the end, these photos of Assad with his family remind us of the common thread that binds us all – the love and connection we share with our loved ones. They humanize a figure often portrayed as a distant and unfeeling leader, prompting us to reflect on the complexities of power, family, and the enduring struggle for peace and justice in Syria.
In addition to refining the definition of sexual harassment, experts stress the need to enhance the punishment mechanisms for offenders. Currently, the consequences for acts of harassment are often inadequate or inconsistent, leading to a lack of deterrence for potential perpetrators. By increasing the severity of penalties for those found guilty of sexual harassment, organizations can send a clear message that such behavior will not be tolerated and will be met with serious repercussions.NoneTrump convinced Republicans to overlook his misconduct. But can he do the same for his nominees?
Biden Dumps Student Loan Forgiveness Plans: What It Means For Borrowers, Loan Providers Like SoFiThese large-cap stocks were the best performers in the last week. Are they in your portfolio? Super Micro Computer, Inc. SMCI shares rocketed 78.42%. The company announced it submitted a compliance plan to Nasdaq . Snowflake Inc. SNOW stock jumped 32.93% after the company reported better-than-expected financial results for the third quarter and raised guidance. Several analysts raised price targets following the print . Williams-Sonoma, Inc. WSM stock escalated 31.63% after the company reported better-than-expected third-quarter 2024 results, announced a new $1 billion buyback program, and raised its outlook . Analysts boosted the price target on the stock . Symbotic Inc. SYM stock zoomed 31.52% after the company reported better-than-expected financial results . Texas Pacific Land Corporation TPL stock rose 27.21%. Amer Sports, Inc. AS stock rose 25.71% after reporting third-quarter results . Multiple analysts raised their respective price targets . Elastic N.V. ESTC shares upped 25.15% after the company reported second-quarter financial results and issued FY25 guidance above estimates . Several analysts boosted the price target on the stock . MicroStrategy Incorporated MSTR shares escalated 23.85% after the company announced it completed its previously announced offering of its 0% convertible senior notes due 2029 . YPF Sociedad Anonima YPF shares increased 23.59%, probably on continued strength after the nation received a credit upgrade from Fitch over the weekend. Datadog, Inc. DDOG stock gained 23.59% last week in sympathy with Snowflake, which reported better-than-expected third-quarter results . Photo by JOCA_PH on Shutterstock © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.Efficient Lions outlast error-prone ColtsTrader Joe’s shoppers call stores ‘a hellish experience’ and reveals two reasons why chain is ‘going downhill’
Franchisee and Area Director supports Colorado and Wyoming operations with dedication and expertise Bobby Rusnak Franchisee and Area Director for Colorado and Wyoming "My role is to support the brand and my fellow franchisees while ensuring we deliver exceptional barbecue experiences to our guests,” Rusnak said. "As an Area Director, I'm focused on strengthening operations and helping franchisees overcome challenges, one store at a time.” Rusnak oversees 15 locations across Colorado, balancing ownership of his stores with responsibilities as an Area Director. This includes guiding franchisees in stabilizing operations and adhering to the high standards Dickey's is known for. "Bobby's ability to lead by example and his deep understanding of the challenges franchisees face make him an exceptional Area Director,” said Roland Dickey Jr., CEO of Dickey's Capital Group. "He is a true partner in growing the brand and supporting our franchisees in achieving their goals.” Laura Rea Dickey , CEO of Dickey's Barbecue Restaurants, Inc., added, "Bobby's story embodies the heart of our brand-stepping up for family and community. His leadership as an Area Director strengthens not only the Dickey's franchise system but also the relationships we value so deeply with our owner-operators.” Under Rusnak's leadership, Dickey's locations in Colorado continue to deliver the slow-smoked barbecue experience that has defined the brand for over 80 years. His commitment ensures franchisees have the tools and resources they need to thrive. "Stepping into this role was about doing what was needed to stabilize and grow the business,” Rusnak said. "It's rewarding to see the impact we're making in our communities and across the region.” Bobby Rusnak's journey underscores Dickey's dedication to empowering franchisees and fostering a collaborative network that drives success. About Dickey's Barbecue Restaurants, Inc. Founded in 1941 by The Dickey Family, Dickey's Barbecue Restaurants, Inc. is the world's largest barbecue concept and continues as a third-generation family-run business. For over 80 years, Dickey's Barbecue Pit has served millions with its signature Legit. Texas. Barbecue.TM Slow-smoked over hickory wood-burning pits, Dickey's barbecued meats are paired with a variety of southern sides. Committed to authentic barbecue, Dickey's never takes shortcuts-because real barbecue can't be rushed. With over 866 restaurants across eight concepts in the U.S. and several countries, Dickey's Barbecue Franchise and Dickey's Restaurant Brands continues to grow under the leadership of Roland Dickey, Jr., CEO of Dickey's Capital Group, and Laura Rea Dickey, CEO of Dickey's Barbecue Pit, Inc. Dickey's has been recognized on Newsweek's 2022 "America's Favorite Restaurant Chains" list, Nation's Restaurant News 2024 top fast-casual brands for value, and USA Today's 2021 Readers' Choice Awards. The brand has also ranked in the Top 20 of Fast Casual's "Top 100 Movers and Shakers” for four of the past five years. Additional accolades include Entrepreneur's Top 500 Franchise and Hospitality Technology's Industry Heroes list. The brand has been featured by Fox News, Forbes, Franchise Times, The Wall Street Journal, and People Magazine . For more information, visit www.dickeys.com . For information about becoming a franchise partner, visit www.dickeysfranchise.com . Attachment Bobby Rusnak CONTACT: Louisa Garrett Dickey's Barbecue Pit [email protected]
Related hot word search:
Previous:
Next: jsbetting